TERN-201 NASH clinical trial : Terns reports positive results for phase 1 study
TERN-201 NASH clinical trial : Terns Pharmaceuticals said that an ongoing phase 1 trial of its semicarbazide-sensitive amine oxidase (SSAO) inhibitor TERN-201 in non-alcoholic steatohepatitis (NASH) has yielded positive results. According to the US biopharma company, the early-stage NASH clinical study showed that a single oral dose of TERN-201 delivered a sustained, near-complete suppression of […]
BIO89-100 NASH clinical trial : US-based biopharma company 89Bio has initiated a proof of concept phase 1b/2a clinical trial for BIO89-100, its NASH drug in development, by screening the first patients. The proof of concept trial will evaluate the glycoPEGylated analog of fibroblast growth factor 21 (FGF21) in patients with nonalcoholic steatohepatitis (NASH) or patients […]
Continue reading …
Business News Today
- Deutsche Börse to acquire majority stake in Quantitative Brokers
- MetLife to acquire vision-care benefits company Versant Health for $1.6bn
- Delivery Hero to acquire Latin American business of Glovo in €230m deal
- Arthur J. Gallagher acquires crop insurance provider Kirksey Agency
- Klarna pockets $650m funding for e-commerce payment solutions
- Amazon India opens two new fulfilment centres in Hyderabad
- Volansi bags $50m in Series B round for middle-mile drone delivery services
- British clothing retailer Next to form JV with Victoria’s Secret UK
- Cocomels launches new Sugar Free Coconut Milk Caramels
- Verizon to acquire US prepaid wireless provider Tracfone Wireless from America Movil
